Stay updated with breaking news from Checkmate 816. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.
Specialists engage in a conversation regarding the treatment duration and the effectiveness of the current two-year approach.
Jarushka Naidoo, MBBCh, discussed the clinical significance of datasets from several phase 3 trials presented at the 2023 ASCO Annual Meeting, including ADAURA, KEYNOTE-617, CheckMate 816, and CheckMate 9LA trials.
Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.
Focused discussion on the selection of neoadjuvant therapy in patients with resectable NSCLC in light of recent clinical trials.